Clinical Trial Update: BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma [Phase 3]

View source ↗

Summary

Phase 3 BEAT-meso trial evaluating bevacizumab and atezolizumab in malignant pleural mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Avastin (bevacizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Pleural Mesothelioma Malignant Advanced | Phase 3 | Status: COMPLETED